Increased aspartate aminotransferase activity of serum after in vitro supplementation with pyridoxal phosphate.
D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood*; D001224:Aspartic Acid / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000201:enzymology; D003124:Colorimetry; D003593:Cytoplasm / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D004912:Erythrocytes / Q000201:enzymology; D005069:Evaluation Studies as Topic; D005260:Female; D005969:Glutamate Dehydrogenase / Q000097:blood; D006801:Humans; D007700:Kinetics; D008113:Liver Neoplasms / Q000201:enzymology; D008297:Male; D008722:Methods; D008875:Middle Aged; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000494:pharmacology*; D012044:Regression Analysis; D006435:Renal Dialysis; D013056:Spectrophotometry, Ultraviolet; D013997:Time Factors
D001224:Aspartic Acid; D011732:Pyridoxal Phosphate; D005969:Glutamate Dehydrogenase; D001219:Aspartate Aminotransferases